Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
PTCH1
REST API REST API
Homo sapiens
PTCH1 is differentially expressed in 351 experiments: 154 organism parts: cerebellum, kidney, ... (152 more);, 225 disease states: normal, colorectal adenocarcinoma, ... (223 more);, 105 cell types 454 cell lines 43 compound treatments and 88 other conditions.
Synonyms BCNS, PTCH, NBCCS
Orthologs PTCH1 (Gallus gallus)   NCR1 (Saccharomyces cerevisiae)   ENSBTAG00000009903 (Bos taurus)   Ptch1 (Mus musculus)   ptch1 (Danio rerio)   Ptch1 (Rattus norvegicus)   ptc (Drosophila melanogaster)   ptch1 (Xenopus laevis)   Q1MW23_BOVIN (Bos taurus)   PTCH1 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term pattern specification process, plasma membrane, protein binding, cell proliferation, regulation of cell proliferation, negative regulation of cell proliferation, negative regulation of smoothened signaling pathway, membrane, heparin binding, heart morphogenesis, regulation of mitotic cell cycle, regulation of protein localization, smoothened signaling pathway, glucose homeostasis, negative regulation of multicellular organism growth, midbody, integral to plasma membrane, protein processing, epidermis development, patched binding, receptor activity, integral to membrane, regulation of smoothened signaling pathway, negative regulation of epithelial cell proliferation, brain development, signal transduction, organ morphogenesis, hedgehog receptor activity, regulation of growth, dorsal/ventral pattern formation, neural tube formation, mammary gland duct morphogenesis, neural tube closure, branching involved in ureteric bud morphogenesis, response to chlorate, mammary gland development, neural plate axis specification, dorsal/ventral neural tube patterning, mammary gland epithelial cell differentiation, embryonic limb morphogenesis, renal system development, keratinocyte proliferation, hindlimb morphogenesis, somite development, cell proliferation involved in metanephros development, cell differentiation involved in kidney development
InterPro Term Patched, TM_rcpt_patched, SSD
UniProt Accession Q3LFT4, Q13635, A3KBF6, Q6TKQ0, Q59FG5, Q5VZC1, Q3LFT3, Q3LG18, Q6ZVG8, F5H3A7, F8VXL8, F8VPA3, F8VQS6
Gene-Disease Assocation HOLOPROSENCEPHALY 7; HPE7, BASAL CELL NEVUS SYNDROME; BCNS, MEDULLOBLASTOMA; MDB, BASAL CELL CARCINOMA, SUSCEPTIBILITY TO, 1; BCC1
Search EB-eye ENSG00000185920
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-GEOD-803, E-GEOD-6573, E-GEOD-7540, E-GEOD-3526, ... (27 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-3860, E-GEOD-17482, E-GEOD-5258, E-MEXP-1006, E-GEOD-19639, ... (45 experiments)

Factor Value U/D Experiments
MCF-7
4
E-GEOD-19639, E-GEOD-3529, E-GEOD-20081, E-GEOD-5823
SW480
4
E-MTAB-37, E-GEOD-18005, E-MEXP-1014, E-GEOD-2509
A549
2
E-GEOD-3202, E-GEOD-6013
MDA-MB-231
2
E-TABM-420, E-MTAB-62
MDAMB453
2
E-MTAB-37, E-MTAB-62
MOLT4
2
E-MTAB-37, E-MTAB-62
448 more value(s).


Cell type

studied in E-GEOD-21668, E-GEOD-3920, E-MEXP-750, E-GEOD-20677, E-GEOD-2822, ... (54 experiments)

Factor Value U/D Experiments
macrophage
1
3
E-GEOD-3982, E-GEOD-22373, E-GEOD-360, E-GEOD-8286
fibroblast
2
E-GEOD-3920, E-GEOD-3204
CD56+ NK cells
2
E-AFMX-5, E-TABM-145
testis - germ cell
2
E-AFMX-5, E-TABM-145
CD3- CD56dim CD62L+ NK cell
1
E-GEOD-21774
CD3- CD56dim CD62L- NK cell
1
E-GEOD-21774
99 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-1577, E-TABM-15, E-GEOD-16363, ... (67 experiments)

Factor Value U/D Experiments
breast carcinoma
3
E-MTAB-37, E-TABM-276, E-GEOD-5823
benign prostatic hyperplasia
3
E-MEXP-2034, E-MEXP-1243, E-GEOD-5377
control
3
E-GEOD-8121, E-GEOD-21912, E-GEOD-16363
lung adenocarcinoma
3
E-MTAB-37, E-MTAB-62, E-GEOD-4127
prostate carcinoma
3
E-MTAB-62, E-MEXP-2034, E-GEOD-5377
acute promyelocytic leukemia
2
E-GEOD-1729, E-MTAB-62
219 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-4668, E-GEOD-5258, E-GEOD-5741, E-GEOD-5542, ... (29 experiments)

Factor Value U/D Experiments
none
4
8
E-GEOD-412, E-MEXP-1601, E-GEOD-5824, E-GEOD-4668, E-TABM-868, ... (12 experiments)
ethanol
2
E-MEXP-2241, E-GEOD-3113
sapphyrin PCI-2054
1
E-GEOD-6400
baseline sevoflurane
1
E-GEOD-4386
ponasterone A
1
E-GEOD-3113
Cxcl12
1
1
E-GEOD-7307
37 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
1
E-GEOD-19519
thapsigargin
1
1
E-GEOD-19519
tunicamycin
1
1
E-GEOD-19519


Biosource provider
studied in E-MTAB-37, E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd3
studied in E-GEOD-22601

cd8
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125, E-GEOD-1729

Clinical history
studied in E-GEOD-22097, E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-TABM-125, ... (10 experiments)

Clinical info
studied in E-GEOD-19743, E-MEXP-1251, E-GEOD-19246, E-GEOD-1563, E-GEOD-21589, ... (15 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-2171, E-GEOD-6532, E-GEOD-21610

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-19743, E-GEOD-1614, E-GEOD-20033, E-GEOD-3140, E-MEXP-2359, ... (8 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-1323, E-GEOD-19743, E-GEOD-3325, E-GEOD-2509, E-GEOD-22148, ... (8 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518

Er
studied in E-GEOD-20194, E-GEOD-16716

Er ihc
studied in E-GEOD-21653

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-MEXP-1482, E-GEOD-7578, E-GEOD-20847, ... (9 experiments)

Genotype
studied in E-MEXP-421, E-GEOD-22593, E-GEOD-2292, E-TABM-321, E-TABM-868, ... (9 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-MEXP-2657, E-GEOD-20540, E-GEOD-22278, E-GEOD-10315, ... (14 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-302, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-TABM-740, E-MEXP-2069, E-MEXP-1648, ... (40 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12254, E-MEXP-561, E-GEOD-980 ... (5 experiments)

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214, E-GEOD-22056, E-GEOD-12662

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-TABM-130, E-MEXP-958, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

Pcr vs rd
studied in E-GEOD-20194, E-GEOD-16716

Performer
studied in E-GEOD-2004, E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-26495, E-GEOD-19703, E-GEOD-1309, E-GEOD-22152, E-GEOD-1493, ... (11 experiments)

Population
studied in E-GEOD-4922, E-GEOD-4342

Pr ihc
studied in E-GEOD-21653

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343 ... (5 experiments)

Replicate
studied in E-GEOD-18791

Rna integrity
studied in E-TABM-325

RNAi
studied in E-MEXP-1422, E-GEOD-12438, E-MEXP-101, E-GEOD-3697, E-MEXP-1857, ... (6 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374, E-GEOD-18995

Sex
studied in E-GEOD-12293, E-GEOD-7307

Sirna
studied in E-GEOD-21575

Stimulation
studied in E-GEOD-20114, E-GEOD-11428

Strain or line
studied in E-MEXP-1996

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-4922, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-33562, E-GEOD-16837, E-MEXP-973, E-GEOD-19246, E-GEOD-13818, ... (7 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Ttf
studied in E-GEOD-21521

Tumor grading
studied in E-GEOD-89, E-GEOD-4290, E-GEOD-4271, E-GEOD-1561

Tumor size
studied in E-GEOD-6532

Vehicle
studied in E-GEOD-5258

weight of protein recovered
studied in E-GEOD-21918

Processing time: 0.313 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM